Clinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis

The Lancet

Volumn 388, Issue 10049, 2016, Pages 1103-1114

  Rich, Josiah D ^a,c,d   Beckwith, Curt G ^a,c   Macmadu, Alexandria ^c   Marshall, Brandon D L ^d   Brinkley Rubinstein, Lauren ^b   Amon, Joseph J ^e   Milloy, M J ^f   King, Maximilian R F ^d   Sanchez, Jorge ^g,h   Atwoli, Lukoye ⁱ   Altice, Frederick L ^j,k  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c MIRIAM HOSPITAL   (United States)

^d BROWN UNIVERSITY   (United States)

^e Health and Human Rights Division   (United States)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g UNMSM Daniel A Carrion Tropical Medicine Institute   (Peru)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ MOI UNIVERSITY   (Kenya)

^j YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k YALE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MANAGEMENT; HEALTH CARE DELIVERY; HEPATITIS B; HEPATITIS C; HIGH INCOME COUNTRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; LOW INCOME COUNTRY; MEDICAL CARE; MENTAL DISEASE; MIDDLE INCOME COUNTRY; PRIORITY JOURNAL; PRISON; PRISONER; PUBLIC HEALTH; REVIEW; SUBSTANCE USE; TUBERCULOSIS; VIRUS HEPATITIS; HEPATITIS, VIRAL, HUMAN; HIV INFECTIONS; MASS SCREENING;

ANTIVIRUS AGENT;

ANTIVIRAL AGENTS; HEPATITIS B; HEPATITIS C; HEPATITIS, VIRAL, HUMAN; HIV INFECTIONS; HUMANS; MASS SCREENING; PRISONERS; TUBERCULOSIS;

EID: 84986288222     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)30379-8     Document Type: Review

References (107)

1. 1 Dolan, K, Wirtz, AL, Moazen, B, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet, 2016 published online July 14. http://dx.doi.org/10.1016/S0140-6736(16)30466-4.
2. 2 Fazel, S, Seewald, K, Severe mental illness in 33 588 prisoners worldwide: systematic review and meta-regression analysis. Br J Psychiatry 200 (2012), 364–373.
3. 3 Rubenstein, LS, Amon, JJ, McLemore, M, et al. HIV, prisoners, and human rights. Lancet, 2016 published online July 14. http://dx.doi.org/10.1016/S0140-6736(16)30663-8.
4. 4 WHO UNAIDS, UNOCD. Effectiveness of interventions to address HIV in prisons, 2007, World Health Organization, Geneva.
5. 5 United Nations Office On Drugs and Crime. HIV prevention, treatment and care in prisons and other closed settings: a comprehensive package of interventions, 2013, United Nations Office of Drugs and Crime, Vienna.
6. 6 Mugavero, MJ, Amico, KR, Horn, T, Thompson, MA, The state of engagement in HIV care in the United States: from cascade to continuum to control. Clin Infect Dis 57 (2013), 1164–1171.
7. 7 Bradley, H, Hall, HI, Wolitski, RJ, et al. Vital signs: HIV diagnosis, care, and treatment among persons living with HIV—United States, 2011. MMWR Morb Mortal Wkly Rep 63 (2014), 1113–1117.
8. 8 Montaner, JS, Lima, VD, Barrios, R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 376 (2010), 532–539.
9. 9 Hull, MW, Wu, Z, Montaner, JS, Optimizing the engagement of care cascade: a critical step to maximize the impact of HIV treatment as prevention. Curr Opin HIV AIDS 7 (2012), 579–586.
10. 10 Althoff, AL, Zelenev, A, Meyer, JP, et al. Correlates of retention in HIV care after release from jail: results from a multi-site study. AIDS Behav 17:suppl 2 (2013), 156–170.
11. 11 Zaller, ND, Holmes, L, Dyl, AC, et al. Linkage to treatment and supportive services among HIV-positive ex-offenders in Project Bridge. J Health Care Poor Underserved 19 (2008), 522–531.
12. 12 UNAIDS. 90-90-90: An ambitious treatment target to help end the AIDS epidemic. Joint United Nations Programme on HIV/AIDS, 2014.
13. 13 Dolan, K, Kite, B, Black, E, Aceijas, C, Stimson, GV, HIV in prison in low-income and middle-income countries. Lancet Infect Dis 7 (2007), 32–41.
14. 14 Meyer, JP, Cepeda, J, Wu, J, Trestman, RL, Altice, FL, Springer, SA, Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate. JAMA Intern Med 174 (2014), 721–729.
15. 15 Flanigan, TP, Zaller, N, Beckwith, CG, et al. Testing for HIV, sexually transmitted infections, and viral hepatitis in jails: still a missed opportunity for public health and HIV prevention. J Acquir Immune Defic Syndr 55:suppl 2 (2010), 78–83.
16. 16 Small, W, Wood, E, Betteridge, G, Montaner, J, Kerr, T, The impact of incarceration upon adherence to HIV treatment among HIV-positive injection drug users: a qualitative study. AIDS Care 21 (2009), 708–714.
17. 17 Belenko, S, Dembo, R, Copenhaver, M, et al. HIV Stigma in Prisons and Jails: Results from a Staff Survey. AIDS Behav 20 (2016), 71–84.
18. 18 Culbert, GJ, Bazazi, AR, Waluyo, A, et al. The influence of medication attitudes on utilisation of antiretroviral therapy (ART) in Indonesian prisons. AIDS Behav 20 (2016), 1026–1038.
19. 19 United Nations Office on Drugs and Crime WHO, UNAIDS. HIV testing and counselling in prisons and other closed settings, 2010, World Health Organization, New York City.
20. 20 Mounier-Jack, S, Nielsen, S, Coker, R, HIV testing strategies across European countries. HIV Med 9:suppl 2 (2008), 13–19.
21. 21 Maruschak, LM, Beavers, R, HIV in Prisons, 2007–08. Bur Justice Stat Bulletin, 2009, 1–12.
22. 22 De Voux, A, Spaulding, AC, Beckwith, C, et al. Early identification of HIV: empirical support for jail-based screening. PloS One, 7, 2012, e37603.
23. 23 Margolis, B, Al-Darraji, HA, Wickersham, JA, Kamarulzaman, A, Altice, FL, Prevalence of tuberculosis symptoms and latent tuberculous infection among prisoners in northeastern Malaysia. Int J Tuberc Lung Dis 17 (2013), 1538–1544.
24. 24 ECDC. Technical report: Surveillance and prevention of hepatitis B and C in Europe, 2010, European Centre for Disease Prevention and Control, Stockholm.
25. 25 Kavasery, R, Maru, DS-R, Sylla, LN, Smith, D, Altice, FL, A prospective controlled trial of routine opt-out HIV testing in a men's jail. PloS One, 4, 2009, e8056.
26. 26 Dolan K. HIV services in prison: a global systematic review. The 20th International AIDS Conference, Melbourne, Australia; July 20–25, 2014.
27. 27 Rosen, DL, Wohl, DA, Schoenbach, VJ, All-cause and cause-specific mortality among black and white North Carolina state prisoners, 1995–2005. Ann Epidemiol 21 (2011), 719–726.
28. 28 Maruschak, LM, HIV in prisons, 2001–2010. Bur Justice Stat Bulletin 20 (2012), 1–12.
29. 29 Maruschak, LM, Berzofsky, M, Unangst, J, Medical problems of state and federal prisoners and jail inmates, 2011–12. Bur Justice Stat Spec Rep, 2015, 1–23.
30. 30 WHO. Prisons and health: partnerships for health in the criminal justice system, 2014, World Health Organization, Geneva.
31. 31 Meyer, JP, Cepeda, J, Taxman, FS, Altice, FL, Sex-related disparities in criminal justice and HIV treatment outcomes: a retrospective cohort study of HIV-infected inmates. Am J Public Health 105 (2015), 1901–1910.
32. 32 Brinkley-Rubinstein, L, Turner, WL, Health impact of incarceration on HIV-positive African American males: a qualitative exploration. AIDS Patient Care STDs 27 (2013), 450–458.
33. 33 Milloy, M, Kerr, T, Buxton, J, et al. Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis 203 (2011), 1215–1221.
34. 34 Zelenev, A, Marcus, R, Kopelev, A, et al. Patterns of homelessness and implications for HIV health after release from jail. AIDS Behav 17:suppl 2 (2013), 181–194.
35. 35 Springer, SA, Pesanti, E, Hodges, J, Macura, T, Doros, G, Altice, FL, Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. Clin Infect Diss 38 (2004), 1754–1760.
36. 36 Spaulding, AC, Seals, RM, McCallum, VA, Perez, SD, Brzozowski, AK, Steenland, NK, Prisoner survival inside and outside of the institution: implications for health-care planning. Am J Epidemiol 173 (2011), 479–487.
37. 37 Springer, SA, Azar, MM, Altice, FL, HIV, alcohol dependence, and the criminal justice system: a review and call for evidence-based treatment for released prisoners. Am J Drug Alcohol Abuse 37 (2011), 12–21.
38. 38 Iroh, PA, Mayo, H, Nijhawan, AE, The HIV care cascade before, during, and after incarceration: a systematic review and data synthesis. Am J Public Health 105 (2015), e5–16.
39. 39 Loutfy, MR, Wu, W, Letchumanan, M, et al. Systematic review of HIV transmission between heterosexual serodiscordant couples where the HIV-positive partner is fully suppressed on antiretroviral therapy. PloS One, 8, 2013, e55747.
40. 40 Altice, FL, Azbel, L, Stone, J, et al. The perfect storm: incarceration and high risk environment perpetuating HIV, HCV and tuberculosis transmission in eastern Europe and central Asia. Lancet, 2016 published online July 14. http://dx.doi.org/10.1016/S0140-6736(16)30856-X.
41. 41 Ko, N-Y, Liu, H-Y, Lai, Y-Y, Pai, Y-H, Ko, W-C, Case management interventions for HIV-infected individuals. Curr HIV/AIDS Rep 10 (2013), 390–397.
42. 42 Teixeira, PA, Jordan, AO, Zaller, N, Shah, D, Venters, H, Health outcomes for HIV-infected persons released from the New York City jail system with a transitional care-coordination plan. Am J Public Health 105 (2015), 351–357.
43. 43 Nunn, A, Cornwall, A, Fu, J, Bazerman, L, Loewenthal, H, Beckwith, C, Linking HIV-positive jail inmates to treatment, care, and social services after release: results from a qualitative assessment of the COMPASS program. J Urban Health 87 (2010), 954–968.
44. 44 Wohl, DA, Scheyett, A, Golin, CE, et al. Intensive case management before and after prison release is no more effective than comprehensive pre-release discharge planning in linking HIV-infected prisoners to care: a randomized trial. AIDS Behav 15 (2011), 356–364.
45. 45 Thompson, MA, Mugavero, MJ, Amico, KR, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med 156 (2012), 817–833.
46. 46 Westergaard, RP, Spaulding, AC, Flanigan, TP, HIV among persons incarcerated in the USA: a review of evolving concepts in testing, treatment, and linkage to community care. Curr Opin Infect Dis 26 (2013), 10–16.
47. 47 Springer, SA, Brown, S-E, Di Paola, A, Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system. Drug Alcohol Depend 157 (2015), 158–165.
48. 48 Hagan, H, The relevance of attributable risk measures to HIV prevention planning. AIDS 17 (2003), 911–913.
49. 49 Jürgens, R, Nowak, M, Day, M, HIV and incarceration: prisons and detention. J Int AIDS Soc, 14, 2011, 26.
50. 50 Kamarulzaman, A, Reid, SE, Schwitters, A, et al. Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. Lancet, 2016 published online July 14. http://dx.doi.org/S0140-6736(16)30769-3.
51. 51 Larney, S, Kopinski, H, Beckwith, CG, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology 58 (2013), 1215–1224.
52. 52 Tsoulfas, G, Goulis, I, Giakoustidis, D, et al. Hepatitis C and liver transplantation. Hippokratia, 13, 2009, 211.
53. 53 Galea, G, Enggist, S, Udesen, C, Møller, L, Prisons and Health, 2014, World Health Organization, 165–170.
54. 54 Macalino, GE, Dhawan, D, Rich, JD, A missed opportunity: hepatitis C screening of prisoners. Am J Public Health 95 (2005), 1739–1740.
55. 55 Hagan, LM, Schinazi, RF, Best strategies for global HCV eradication. Liver Int 33:suppl 1 (2013), 68–79.
56. 56 Kuncio, DE, Newbern, EC, Fernandez-Vina, MH, Herdman, B, Johnson, CC, Viner, KM, Comparison of risk-based hepatitis C screening and the true seroprevalence in an urban prison system. J Urban Health 92 (2015), 379–386.
57. 57 He, T, Li, K, Roberts, MS, et al. Prevention of hepatitis C by Screening and Treatment in U.S. Prisons. Ann Intern Med 164 (2016), 84–92.
58. 58 Rich, JD, Allen, SA, Williams, BA, Responding to hepatitis C through the criminal justice system. N Engl J Med 370 (2014), 1871–1874.
59. 59 Arain, A, Robaeys, G, Stöver, H, Hepatitis C in European prisons: a call for an evidence-informed response. BMC Infect Dis, 14(suppl 6), 2014, S17.
60. 60 Spaulding, AS, Kim, AY, Harzke, AJ, et al. Impact of new therapeutics for hepatitis C virus infection in incarcerated populations. Top Antivir Med 21 (2013), 27–35.
61. 61 Zampino, R, Coppola, N, Sagnelli, C, Di Caprio, G, Sagnelli, E, Hepatitis C virus infection and prisoners: Epidemiology, outcome and treatment. World J Hepatol 7 (2015), 2323–2330.
62. 62 Liu, S, Watcha, D, Holodniy, M, Goldhaber-Fiebert, JD, Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis. Ann Intern Med 161 (2014), 546–553.
63. 63 Larney, S, Beckwith, CG, Zaller, ND, Montague, BT, Rich, J, “Seek, test, treat and retain” for hepatitis C in the United States criminal justice system. Int J Prison Health 10 (2014), 164–171.
64. 64 Azbel, L, Wickersham, JA, Grishaev, Y, Dvoryak, S, Altice, FL, Burden of infectious diseases, substance use disorders, and mental illness among Ukrainian prisoners transitioning to the community. PloS One, 8, 2013, e59643.
65. 65 Azbel, L, Wickersham, JA, Grishaev, Y, Dvoryak, S, Altice, FL, Correlates of HIV infection and being unaware of HIV status among soon-to-be-released Ukrainian prisoners. J Int AIDS Soc, 17, 2014, 19005.
66. 66 Azbel, L, Wickersham, JA, Wegman, MP, et al. Burden of substance use disorders, mental illness, and correlates of infectious diseases among soon-to-be released prisoners in Azerbaijan. Drug Alcohol Depend 151 (2015), 68–75.
67. 67 Mitruka, K, Tsertsvadze, T, Butsashvili, M, et al. Launch of a nationwide hepatitis C elimination program—Georgia, April 2015. MMWR Morb Mortal Wkly Rep 64 (2015), 753–757.
68. 68 Graham, CS, Swan, T, A path to eradication of hepatitis C in low-and middle-income countries. Antiviral Res 119 (2015), 89–96.
69. 69 WHO/UNICEF coverage estimates 2014 revision. July 2015 Immunization Vaccines and Biologicals, (IVB), World Health Organization. http://www.who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/passive/HepB_coverage.jpg?ua=1, July 24, 2015 [accessed March 30, 2016].
70. 70 Ott, JJ, Stevens, GA, Groeger, J, Wiersma, ST, Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30 (2012), 2212–2219.
71. 71 Larney, S, Monkley, DL, Indig, D, Hampton, SE, A cross-sectional study of susceptibility to vaccine-preventable diseases among prison entrants in New South Wales. MedJ Aust 198 (2013), 376–379.
72. 72 Beck, CR, Cloke, R, O'Moore, É, Puleston, R, Hepatitis B vaccination coverage and uptake in prisons across England and Wales 2003–2010: A retrospective ecological study. Vaccine 30 (2012), 1965–1971.
73. 73 Hutchinson, SJ, Wadd, S, Taylor, A, et al. Sudden rise in uptake of hepatitis B vaccination among injecting drug users associated with a universal vaccine programme in prisons. Vaccine 23 (2004), 210–214.
74. 74 Costumbrado, J, Stirland, A, Cox, G, et al. Implementation of a hepatitis A/B vaccination program using an accelerated schedule among high-risk inmates, Los Angeles County Jail, 2007–2010. Vaccine 30 (2012), 6878–6882.
75. 75 Dara, M, Chadha, SS, Vinkeles Melchers, NV, et al. Time to act to prevent and control tuberculosis among inmates. Int J Tuberc Lung Dis 17 (2013), 4–5.
76. 76 Raviglione, M, Global TB Director. Global strategy and targets for tuberculosis prevention, care and control after 2015, 2013, World Health Organization, Geneva.
77. 77 Rodrigues, C, Vadwai, V, Tuberculosis: laboratory diagnosis. Clin Lab Med 32 (2012), 111–127.
78. 78 Meyer-Rath, G, Schnippel, K, Long, L, et al. The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PloS One, 7, 2012, e36966.
79. 79 Melchers, NVV, Van Elsland, SL, Lange, JM, Borgdorff, MW, Van Den Hombergh, J, State of affairs of tuberculosis in prison facilities: a systematic review of screening practices and recommendations for best TB control. PloS One, 8, 2013, e53644.
80. 80 Carbone Ada, S, Paiao, DS, Sgarbi, RV, et al. Active and latent tuberculosis in Brazilian correctional facilities: a cross-sectional study. BMC Infect Dis, 15, 2015, 24.
81. 81 Kowada, A, Cost-effectiveness of interferon-gamma release assay for entry tuberculosis screening in prisons. Epidemiol Infect 141 (2013), 2224–2234.
82. 82 Al-Darraji, HA, Abd Razak, H, Ng, KP, Altice, FL, Kamarulzaman, A, The diagnostic performance of a single GeneXpert MTB/RIF assay in an intensified tuberculosis case finding survey among HIV-infected prisoners in Malaysia. PloS One, 8, 2013, e73717.
83. 83 Dara, M, Acosta, CD, Melchers, NV, et al. Tuberculosis control in prisons: current situation and research gaps. IntJ Infect Dis 32 (2015), 111–117.
84. 84 Abebe, D, Bjune, G, Ameni, G, Biffa, D, Abebe, F, Prevalence of pulmonary tuberculosis and associated risk factors in Eastern Ethiopian prisons. Int J Tuberc Lung Dis 15 (2011), 668–673.
85. 85 Banda, HT, Gausi, F, Harries, AD, Salaniponi, FM, Prevalence of smear-positive pulmonary tuberculosis among prisoners in Malawi: a national survey. Int J Tuberc Lung Dis 13 (2009), 1557–1559.
86. 86 Al-Darraji, HA, Kamarulzaman, A, Altice, FL, Isoniazid preventive therapy in correctional facilities: a systematic review. Int J Tuberc Lung Dis 16 (2012), 871–879.
87. 87 Aerts, A, Habouzit, M, Mschiladze, L, et al. Pulmonary tuberculosis in prisons of the ex-USSR state Georgia: results of a nation-wide prevalence survey among sentenced inmates. Int J Tuberc Lung Dis 4 (2000), 1104–1110.
88. 88 Shah, SA, Mujeeb, SA, Mirza, A, Nabi, KG, Siddiqui, Q, Prevalence of pulmonary tuberculosis in Karachi juvenile jail, Pakistan. East Mediterr Health J 9 (2003), 667–674.
89. 89 Aerts, A, Hauer, B, Wanlin, M, Veen, J, Tuberculosis and tuberculosis control in European prisons. Int J Tuberc Lung Dis 10 (2006), 1215–1223.
90. 90 Dara, M, Grzemska, M, Kimerling, ME, Reyes, H, Zagorskiy, A, Guidelines for control of tuberculosis in prisons, 2009, World Health Organization, Washington, DC.
91. 91 Biadglegne, F, Rodloff, AC, Sack, U, Review of the prevalence and drug resistance of tuberculosis in prisons: a hidden epidemic. Epidemiol Infect 143 (2015), 887–900.
92. 92 Rich, JD, Wakeman, SE, Dickman, SL, Medicine and the epidemic of incarceration in the United States. N Engl J Med 364 (2011), 2081–2083.
93. 93 Baral, S, Beyrer, C, Muessig, K, et al. Burden of HIV among female sex workers in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis 12 (2012), 538–549.
94. 94 Walmsley, R, World female imprisonment list, 2006, International Centre for Prison Studies, King's College London, London, 1–6.
95. 95 Youmans, E, Burch, J, Moran, R, Smith, L, Duffus, WA, Epidemiological characteristics of HIV-infected women with and without a history of criminal justice involvement in South Carolina. J Correct Health Care 19 (2013), 15–26.
96. 96 American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5(R)). American Psychiatric Pub, 2013.
97. 97 Rich, JD, McKenzie, M, Larney, S, et al. Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. Lancet 386 (2015), 350–359.
98. 98 Geneva Declaration 2012 on health care in prison. 6th European Conference on Health Promotion in Custody; February 1-3, 2012.
99. 99 World Health Organization. Health in prisons: A WHO guide to the essentials in prison health, 2007, World Health Organization Regional Office for Europe, Copenhagen.
100. 100 United Nations Economic and Social Council. United Nations standard minimum rules for the treatment of prisoners (the Mandela Rules), 2015, Commission on Crime Prevention and Criminal Justice, Vienna May 18–22.
101. 101 Van Biljon and others v. Minister of Correctional Services. Reference: 6 BCLR 789; 1997.
102. 102 Tapela and others v. Attorney General and others. Reference: MAHGB-000057-14; 2014.
103. 103 Testa and others v. Croatia. Reference: 20877/04; 2007.
104. 104 Staykov and others v. Bulgaria. Reference: 49438/99; 2007.
105. 105 Office of the High Commissioner for Human Rights. CESCR General Comment No. 14: The right to the highest attainable standard of health (Art. 12); 2000. Document E/C.12/2000/4.
106. 106 Arora, S, Thornton, K, Jenkusky, SM, Parish, B, Scaletti, JV, Project ECHO: linking university specialists with rural and prison-based clinicians to improve care for people with chronic hepatitis C in New Mexico. Public Health Rep 122:suppl 2 (2007), 74–77.
107. 107 Arora, S, Kalishman, S, Thornton, K, et al. Expanding access to hepatitis C virus treatment—Extension for Community Healthcare Outcomes (ECHO) project: disruptive innovation in specialty care. Hepatology 52 (2010), 1124–1133.